Immatics (IMTX) Non-Current Assets (2019 - 2026)
Immatics (IMTX) posted Non-Current Assets of $67.9 million for Q4 2025, down 4.06% sequentially from $70.8 million in Q3 2025, and down 4.58% YoY from $71.2 million in Q4 2024.
Analysis
Immatics (IMTX) Non-Current Assets (2019 - 2026) Analysis & Trends
Immatics has reported Non-Current Assets for 7 years, with the latest figure at $67.9 million in Q4 2025.
- Quarterly Non-Current Assets fell 4.58% year-over-year to $67.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $67.9 million (down 4.58% YoY) and the FY2025 annual result came in at $65.9 million, down 8.57% from the prior year.
- Non-Current Assets eased to $67.9 million in Q4 2025 per IMTX's latest filing, from $70.8 million in the prior quarter.
- Over five years, Non-Current Assets peaked at $73.1 million in Q2 2024 and troughed at $19.0 million in Q1 2021.
- A 5-year average of $49.3 million and a median of $53.4 million in 2023 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2023 and 2025: Non-Current Assets soared 108.38% in 2023, then declined 4.58% in 2025.
- Over 5 years, Non-Current Assets stood at $25.7 million in 2021, then grew by 21.88% to $31.3 million in 2022, then jumped by 108.38% to $65.2 million in 2023, then increased by 9.15% to $71.2 million in 2024, then dropped by 4.58% to $67.9 million in 2025.
- According to Business Quant data, Non-Current Assets over the past three periods registered $67.9 million, $70.8 million, and $71.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 5.15 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 294.93 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 1.96 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 938.60 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 18.06 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Immatics | 1.17 Bn | 711.21 Mn | - | 65.72 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 65.72 Mn |
| Mar 31, 2026 | 68.40 Mn |
| Dec 31, 2025 | 67.90 Mn |
| Sep 30, 2025 | 70.77 Mn |
| Jun 30, 2025 | 71.73 Mn |
| Mar 31, 2025 | 71.66 Mn |
| Dec 31, 2024 | 71.16 Mn |
| Sep 30, 2024 | 70.79 Mn |
| Jun 30, 2024 | 73.07 Mn |
| Mar 31, 2024 | 70.32 Mn |
| Dec 31, 2023 | 65.20 Mn |
| Sep 30, 2023 | 57.09 Mn |
| Jun 30, 2023 | 49.62 Mn |
| Mar 31, 2023 | 35.89 Mn |
| Dec 31, 2022 | 31.29 Mn |
| Sep 30, 2022 | 32.25 Mn |
| Jun 30, 2022 | 34.44 Mn |
| Mar 31, 2022 | 24.99 Mn |
| Dec 31, 2021 | 25.67 Mn |
| Sep 30, 2021 | 22.14 Mn |